Literature DB >> 15514525

A hemoglobin based oxygen carrier, bovine polymerized hemoglobin (HBOC-201) versus Hetastarch (HEX) in an uncontrolled liver injury hemorrhagic shock swine model with delayed evacuation.

Jennifer Gurney1, Nora Philbin, Jennifer Rice, Françoise Arnaud, Feng Dong, Meghan Wulster-Radcliffe, L Bruce Pearce, Lewis Kaplan, Richard McCarron, Daniel Freilich.   

Abstract

BACKGROUND: As HBOC-201 improves outcome in animals with hemorrhagic shock (HS), we compared HBOC-201 and HEX (used by U.S. military special operations forces) in a swine model of delayed evacuation and uncontrolled HS.
METHODS: Twenty-four Yucatan pigs underwent a grade III liver injury and were resuscitated with HBOC-201, HEX, or no fluid (NON). Additional infusions were given for hypotension or tachycardia. After 4 hours, the liver was repaired; IV fluids and blood transfusions were administered. Pigs were monitored for 72 hours.
RESULTS: Survival was 7/8, 1/8, and 1/8 in HBOC-201-, HEX-, and NON-resuscitated pigs, respectively. Compared with HEX, HBOC-201 pigs had higher systemic and pulmonary artery pressures and had comparable cardiac outputs, but were less tachycardic. Transcutaneous tissue oxygenation was restored more rapidly in HBOC-201 pigs, there was a trend to lower lactic acid, and base deficit was less. HBOC-201 pigs had lower fluid requirements, higher urine output, and lower blood loss than HEX pigs.
CONCLUSIONS: Despite evidence of vasoactivity, HBOC-201 more effectively stabilized tissue oxygenation, reversed anaerobic metabolism, decreased bleeding, and increased survival in comparison with HEX. If confirmed in clinical trials, these data suggest that for the resuscitation of combat casualties with delayed evacuation and uncontrolled HS due to solid organ injury, HBOC-201 is a superior low-volume resuscitative fluid.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15514525     DOI: 10.1097/01.ta.0000147520.84792.b4

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  7 in total

1.  Polynitroxylated Pegylated Hemoglobin-A Novel, Small Volume Therapeutic for Traumatic Brain Injury Resuscitation: Comparison to Whole Blood and Dose Response Evaluation.

Authors:  Erik C Brockman; Travis C Jackson; C Edward Dixon; Hülya Bayɪr; Robert S B Clark; Vincent Vagni; Keri Feldman; Catherine Byrd; Li Ma; Carleton Hsia; Patrick M Kochanek
Journal:  J Neurotrauma       Date:  2017-01-13       Impact factor: 5.269

2.  Storage of nitroglycerin (NTG) admixed with HBOC-201 for 30 days in polyolefin plastic bags: a pilot study.

Authors:  Savita Nigam; Richard McCarron; Francoise Arnaud
Journal:  Drug Deliv Transl Res       Date:  2017-10       Impact factor: 4.617

3.  Glutaraldehyde-polymerized bovine hemoglobin and phosphodiesterase-5 inhibition.

Authors:  Robert W Gotshall; Karyn L Hamilton; Benjamin Foreman; Martha C Tissot van Patot; David C Irwin
Journal:  Crit Care Med       Date:  2009-06       Impact factor: 7.598

Review 4.  Intravenous hemostats: challenges in translation to patients.

Authors:  Margaret Lashof-Sullivan; Andrew Shoffstall; Erin Lavik
Journal:  Nanoscale       Date:  2013-10-02       Impact factor: 7.790

5.  Engineering Intravenously Administered Nanoparticles to Reduce Infusion Reaction and Stop Bleeding in a Large Animal Model of Trauma.

Authors:  Chimdiya Onwukwe; Nuzhat Maisha; Mark Holland; Matt Varley; Rebecca Groynom; DaShawn Hickman; Nishant Uppal; Andrew Shoffstall; Jeffrey Ustin; Erin Lavik
Journal:  Bioconjug Chem       Date:  2018-07-09       Impact factor: 4.774

6.  Development of a Sensitive Assay to Screen Nanoparticles in vitro for Complement Activation.

Authors:  Nuzhat Maisha; Tobias Coombs; Erin Lavik
Journal:  ACS Biomater Sci Eng       Date:  2020-07-06

Review 7.  New Applications of HBOC-201: A 25-Year Review of the Literature.

Authors:  Min Cao; Yong Zhao; Hongli He; Ruiming Yue; Lingai Pan; Huan Hu; Yingjie Ren; Qin Qin; Xueliang Yi; Tao Yin; Lina Ma; Dingding Zhang; Xiaobo Huang
Journal:  Front Med (Lausanne)       Date:  2021-12-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.